Coherus Oncology (CHRS) Net Margin (QoQ) (2013 - 2026)

Coherus Oncology (CHRS) Net Margin (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -7,959.00
Dec 31, 2025 -938.00
Sep 30, 2025 -326,376.00
Jun 30, 2025 346,210.00
Mar 31, 2025 -6,116.00
Dec 31, 2024 -66,838.00
Sep 30, 2024 20,161.00
Jun 30, 2024 -699,791.00
Mar 31, 2024 749,219.00
Dec 31, 2023 -3,387.00
Sep 30, 2023 1,985.00
Jun 30, 2023 16,046.00
Mar 31, 2023 -10,367.00
Dec 31, 2022 6,095.00
Sep 30, 2022 -10,738.00
Jun 30, 2022 7,646.00
Mar 31, 2022 -9,755.00
Dec 31, 2021 -1,558.00
Sep 30, 2021 -1,258.00
Jun 30, 2021 17,417.00